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Abstract
The multifactorial nature of disease motivates the use of systems-level analyses to understand their pathology. We used a
systems biology approach to study tau aggregation, one of the hallmark features of Alzheimer’s disease. A mathematical
model was constructed to capture the current state of knowledge concerning tau’s behavior and interactions in cells. The
model was implemented in silico in the form of ordinary differential equations. The identifiability of the model was assessed
and parameters were estimated to generate two cellular states: a population of solutions that corresponds to normal tau
homeostasis and a population of solutions that displays aggregation-prone behavior. The model of normal tau homeostasis
was robust to perturbations, and disturbances in multiple processes were required to achieve an aggregation-prone state.
The aggregation-prone state was ultrasensitive to perturbations in diverse subsets of networks. Tau aggregation requires
that multiple cellular parameters are set coordinately to a set of values that drive pathological assembly of tau. This model
provides a foundation on which to build and increase our understanding of the series of events that lead to tau aggregation
and may ultimately be used to identify critical intervention points that can direct the cell away from tau aggregation to aid
in the treatment of tau-mediated (or related) aggregation diseases including Alzheimer’s.
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Introduction
Despite the fidelity of protein folding and the operation of
quality control mechanisms to eliminate misfolded and otherwise
abnormal proteins, a number of diseases can be traced to defects in
these processes [1]. Among them are many neurodegenerative
disorders, including the tauopathies, which are characterized by
the intraneuronal aggregation of tau protein and of which
Alzheimer’s disease (AD) is an example. Preventing aggregation
to halt or reverse cognitive decline is the goal of many drug
discovery programs, but effective, long-term treatments have yet to
be discovered [2].
A convincing body of evidence implicates defective tau
processing and the formation of intraneuronal tau aggregates in
cognitive decline. Mutations in the gene encoding tau protein are
directly responsible for a number of genetic conditions collectively
called primary tauopathies, among which is frontotemporal
dementia and Parkinsonism linked to chromosome 17 (FTDP-
17) [3,4]. Tau pathology is also present in a large number of
conditions whose cause cannot be traced to mutations in the gene
encoding tau, including traumatic brain injury and repeated head
trauma (dementia pugilista) from contact sports [5–7] as well as
Alzheimer’s disease, and has been observed with and without
amyloid-beta pathology. Post-mortem assessment of the neurofi-
brillary tangle load in the brains of demented human patients
showed that the severity of dementia was well correlated with the
presence of tangles, a finding that argues strongly that tau plays a
central role in disease progression [8–10]. In addition, the deficits
in spatial learning and memory observed in mouse models
expressing human APP can be ameliorated by reducing endog-
enous, wild-type tau [11], which also protects against early
mortality and inhibits excitoxicity; this finding is supported by
more recent experiments in an AB-forming mouse model [12].
Taken together, these studies point to tau as a key causative factor
in neurodegeneration and suggest that the tau pathway itself
represents a reasonable therapeutic target for diseases in which the
abnormal tau processing pathway is triggered.
Tau is a neuronal, microtubule-associated protein (MAP) whose
physiological function is to regulate microtubule dynamics (Figure
S1). Alternative mRNA splicing yields 6 protein isoforms that are
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or 4 microtubule binding repeats; they are known as the 3R and
4R isoforms, respectively [13,14]. The 4R isoforms have a higher
affinity for microtubules and greater tendency to aggregate [15–
18]. A phospho-protein with nearly 30 phosphorylation sites, tau’s
biological activity is also governed by its phosphorylation state. In
a healthy neuron, tau contains 2–3 moles of phosphate per mole of
tau and is found almost entirely bound to microtubules [19]. In
degenerating neurons, kinase and phosphatase activity is dysreg-
ulated and an abnormal variant containing 5–9 mol phosphate/
mol tau is generated. While normal amounts of physiological tau
are maintained, high amounts of hyper- and abnormally
phosphorylated tau with low affinity for microtubules and
resistance to degradation are generated [20]. These tau species
dissociate from microtubules and collect in the cytosol, where they
subsequently misfold and aggregate. The presence of ubiquitin, a
molecular tag that facilitates degradation by the proteasome, in the
aggregates suggests a failure of the quality control systems that
clear aberrant proteins, contribute to the accumulation of
abnormal tau and the neurofibrillary tangles [21]. Experiments
demonstrating that the ubiquitous, constitutively expressed
chaperone Hsc70 binds tau support this view, as Hsc70 is a
chaperone known to mediate a protein triage decision that results
in either refolding or degradation [22]. When the cell’s quality
control systems fail, tau aggregates and eventually neuron death
occurs. The long, insoluble filaments that form may serve as a
‘stop-gap’ measure to protect the cell from adverse consequences
by sequestering toxic intermediates. However, the actual toxic
moiety among various pathological tau states has not been
conclusively determined.
The multifactorial nature of disease motivates our systems
biology approach to understanding tau pathophysiology. We have
developed a computational model that represents the network of
interactions in which tau is involved as a system of ordinary
differential equations that describe the deterministic chemical
kinetics. The model was tuned to capture observed behavior in a
healthy neuron and an aggregation-prone neuron. Although the
class of tauopathies contains several diseases, specific experimental
data from Alzheimer’s disease studies informed this model.
Sensitivity analysis tools were used to interrogate the model and
ascertain the relative contributions of each component in the tau
pathway from its synthesis to its post-translational modifications, to
its degradation. Within both populations of neurons, and
particularly the aggregation-prone population, we found ultrasen-
sitive cellular conditions that are likely to be resistant to rescue.
Results
Model structure
As one of the first attempts at in silico simulation of tau
pathophysiology, a mathematical model representative of the
known biology was established within the limitations of the
available data (Figure 1). Although this model is necessarily a
simplified version of reality, it captures essential features of the
known tau network and could be easily extended to incorporate
additional detail as new data is generated. Among the key
components are the 3R and 4R isoforms of tau. Alternative
splicing of other tau exons was not considered in the model;
therefore we modeled two species to be representative of the 3R
and 4R classes. The isoform classes were divided into a number of
phospho-states; although there are likely many disease-relevant
phospho-isoforms, for simplicity, each 3R and 4R form was
divided into in a minimally phosphorylated, normally phosphor-
ylated, or abnormally phosphorylated/conformationally altered
state. Minimally phosphorylated 3R and 4R tau are constitutively
produced in a single reaction that captures transcription and
translation. Specific tau kinases and phosphatases such as GSK3-b
and PP5A were not explicitly included in the model. The kinetics
of phospho-isoform conversion were modeled using Michaelis-
Menten kinetics and based on in vivo data, from which the bounds
on the Michaelis-Menten constants and the dependence of the
kinetics on the phospho-state were derived. Tubulin, the building
block of microtubules, was included although the total pool of
tubulin with which tau interacts was considered constant
throughout these analyses. Makrides and colleagues [23] moni-
tored the in vitro reaction kinetics between tau and pre-assembled
microtubules and found that a two-step mechanism in which
either tau or tubulin underwent a conformational change before
binding fit the data best; we employed that two-step mechanism
here, assuming the conformational change occurred in the tau
protein prior to association. Tau degradation by the proteasome
has been shown both in vitro and in vivo in neuronal cell culture
[24], and has also been shown that natively unfolded tau can be
degraded by the 20S proteasome in a non-ubiquitin dependent
manner [25]. This degradation process was modeled with first
order kinetics and a constant pool of proteasomes.
Abnormal 3R and 4R tau are bound by the chaperone Hsc70
[22], which mediates a choice between rescue and ubiquitin-
dependent degradation. We assumed a simple, reversible binding
reaction that does not involve ATP; although Hsp70 is usually an
ATP-dependent chaperone, recent evidence suggests it binds tau
independently of ATP [22]. Rescue is facilitated by the chaperone
Hsp90 [26,27]; although other proteins such as the peptidyl-prolyl
isomerase PIN1 are likely to participate in this pathway [28], we
assumed a simple mechanism by which Hsp90 binds abnormal
tau. In this simplification, abnormal tau is dephosphorylated and
restored to its normal functional form upon Hsp90 binding, and is
released to re-bind microtubules. CHIP, an Hsc70-interacting
protein and E3 ligase, links the chaperone and degradation
machineries and shuttles abnormal tau to the 26S proteasome
[29,30]. BAG-2 binds with the CHIP-Hsc70-Tau complex and
subsequently dissociates with CHIP, restoring the Hsc70-Tau
Author Summary
Neurodegenerative disorders, particularly the tauopathy
Alzheimer’s disease, affect millions of people and cost
billions of dollars a year in healthcare costs. Although
effective treatments to delay or reverse cognitive decline
are still unavailable, several approaches to address this
medical need are being pursued. One such strategy
involves ameliorating aberrant tau processing, as the
characteristic tau tangles associated with the tauopathies
are well-correlated with cognitive dysfunction, genetic
mutations in tau lead directly to neurodegeneration, and
experiments in animal models have yielded promising
results. Two avenues are currently being explored:
inhibition of kinase activity to reduce the presence of
aberrant, hyperphosphorylated tau and means to prevent
and reduce tau aggregation. We have taken a systems
biology approach to understanding tau pathophysiology,
creating a mathematical model to quantitatively explore
the vulnerabilities in the tau network and identify effective
intervention points. Our analysis of the resulting in silico
neuron populations, representing healthy and aggrega-
tion-prone neurons, highlights the multifactorial nature of
the disease and provides insight into pathological triggers
and the timing of treatment, which will be an important
element in effectively treating patients.
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degradation [31,32]. Alternatively, CHIP and Hsc70 can release
ubiquitinated, abnormal tau in a single-step reaction, after which
tau is degraded. Because tau has been shown to be abnormally
phosphorylated prior to ubiquitination, we assumed that only the
abnormal tau species could be degraded in a ubiquitin-dependent,
chaperone-assisted manner [33]. Aggregation is an alternate
pathway down which abnormal tau can travel. Tau aggregation
was modeled with the nucleation-elongation reaction mechanism
and kinetics established by Congdon et. al. They monitored in vitro
tau fibrillization and found that a tau dimer acted as the nucleus
for the reaction, best fitting the experimental data and providing a
good prediction of the length distribution of aggregates through
time [34]. We assumed that only abnormal, ubiquitinated tau
could polymerize as the presence of ubiquitin in tau aggregates is
well-established [35,36] and full-length, wild-type tau does not
aggregate readily under physiological conditions in vitro in the
absence of polymerization promoters because it is hydrophilic and
relatively unstructured [18]. Although normal tau may be
sequestered by abnormal tau and thus aggregate [37], this
mechanism was excluded from our construction due to a paucity
of available data. Furthermore, the paired helical filaments into
which abnormal tau aggregates in Alzheimer’s disease patients
contain 3–4 times more phosphate than physiological tau and the
level of phosphorylation observed in soluble amorphous tau is
similarly elevated, suggesting that paired helical filaments are
primarily comprised of abnormal tau [19,38]. In a study of brains
from patients diagnosed with the tauopathy FTDP-17, in whom
tau is mutated, the insoluble fraction was observed to have a much
greater ratio of mutated tau than normal tau [39], also supporting
this assumption. The effect of macromolecular crowding was also
neglected for parsimony. Excluding these mechanisms from our
model is likely to have little effect on the qualitative results,
resulting in a re-scaling of parameters but not substantially
changing the qualitative behavior and overall conclusions.
Mass action kinetics described all reactions in the network
except the phosphorylation and dephosphorylation reactions,
which were described by Michaelis-Menten kinetics. For each
species represented by our model, an ordinary differential
equation that describes the species time-evolution was constructed
as illustrated in Eq. S1. In total, the network contains 84 reactions,
93 parameters, and 45 states (i.e., differential equations). A full
listing of the states, reactions, parameters, and differential
equations can be found in Tables S1 and S2.
A priori identifiability
Parameter space for the healthy and aggregation-prone
identifiability and optimization steps is different, as the chaperone
and degradation machinery was considered to be operating
homeostatically. As a result, before initiating each stage of the
optimization, an a priori identifiability analysis was completed.
Correlation matrices were calculated at 1024 quasi-random points
in the relevant parameter space, each matrix was weighted based
on the objective function value determined at its corresponding
location in parameter space, and then the matrices were averaged
to establish pseudo-global a priori identifiability.
The results of both stages of this analysis confirm that the
proposed model is a priori identifiable and, by extension,
structurally identifiable (Figures S2 and S3). To improve the
efficiency of the optimizations, we did remove three parameters
(k1,k 84,k 10) from the first stage of the procedure as they were
highly correlated (.0.95).
Establishing healthy neuron models
In the next step, we optimized parameters to achieve steady-state
behavior that represents healthy neuron function. Parameters
Figure 1. Model structure of tau pathophysiology for a single isoform. The network captures tau phosphorylation and dephosphorylation,
microtubule binding and release, uptake, rescue, and degradation by the chaperone machinery, and aggregation. Specifically, unphosphorylated tau
(Tau0) can be degraded or phosphorylated, producing normally phosphorylated tau (TauN). TauN can also be degraded in a non-ubiquitin
dependent fashion, dephosphorylated, or phosphorylated to create abnormal tau (TauH), which can likewise be degraded, dephosphorylated, or
phosphorylated. Each of these free tau species undergoes a conformation change to produce a form with high affinity for microtubules; these species
are denoted with a star as Tau0*, TauN*, and TauH*. Abnormal TauH is taken up by the chaperone Hsp70, which mediates the decision between
rescue and degradation. Both isoforms participate in the same series of reactions, but at different rates of reaction, and their behavior is coupled
through the chaperone and degradation machinery.
doi:10.1371/journal.pcbi.1000997.g001
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bule binding and release, synthesis, and ubiquitin-independent
degradation were estimated. We also estimated ATP synthesis and
depletion. Parameters were generally assumed isoform-indepen-
dent, with the exception of the microtubule binding parameters and
aggregation parameters. Because evidence suggests that 4R tau has
a greater affinity for microtubules [15–17] and for aggregation,
these parameters were increased relative to the corresponding
reactions involving 3R tau. Estimating chaperone and degradation
parameters was excluded from the healthy state computations
because under normal conditions Hsc70 does not bind microtubule
bound tau [22]. Although Hsc70 may bind free normal tau species,
these species represent a small portion of total tau and thus the
model was simplified to exclude these minor interactions.
The objective function that mathematically quantifies the
behavior of a healthy neuron was constructed to reflect known
quantitative experimental data. It is well-established that aberrant
tau species areundetectable in normal neurons; thus we require that
free and microtubule-bound aberrant tau is minimized. From
measurement of total tau in human brain homogenates [40], and
assuming total protein concentration is 500 mg/ml [41], the total
neuronal concentration of tau protein was estimated to be 5–
10 mM, consistentwithmany reported values. Inadult humanbrain
that is not afflicted by Alzheimer’s, the ratio of 3R to 4R tau was
determined to be 1:1 [14,42]. The affinity of normal tau for
microtubules is 16 nM [23] and at least 80% of the total neuronal
tau is bound to microtubules. These data are quantified in a cost
function that sums the squared percent difference between the
model result and the experimental results. Several of the objectives
in our cost function are ‘‘fuzzy’’, i.e. they allow states to achieve a
range of values without penalty, rather than admitting only a single
value withoutpenalty.Thisconstructionis a betterrepresentation of
biological systems than those that force the system to converge to a
single value for objectives such as species concentrations, because it
captures the intrinsic variability of these systems and it results in a
large population of equally feasible parameter sets. A global solver
that uses a scatter-search method followed by refinement with a
local, gradient-based method handles the flat expanses of the search
space. The sample code given in Eq. S2 demonstrates the
implementation of this type of multi-objective, fuzzy cost function.
Necessarily, the solution in this case is not unique. Therefore, a
set of 2500 optimizations was performed in which the model was
run to steady-state, then evaluated against these objectives to
generate a set of equally valid parameter vectors with which to
initialize the model (Dataset S1); qualitatively, the number of
optimizations does not affect the results. For this stage, the only
species for which an initial condition was needed was microtu-
bules; we assume 15 mM tubulin is present in abundance and
excess over tau, and therefore do not include synthesis and
degradation reactions for them. A total of 31 parameters were
estimated. The resulting set of parameter vectors represents a
population of neurons that behave in a healthy fashion and
provides a way of evaluating the range of possible responses the
system can display.
Sensitivity of the healthy neuron population
The median sensitivity of the population to perturbations in the
parameters was calculated at steady-state, to provide insight into
the triggers that disturb the system’s homeostasis (Figure 2). The
95% confidence interval for the sensitivities was also calculated
(Figure S4). Because the ratio of 3R to 4R tau is 1:1 in healthy
neurons, the results for each are equivalent.
The identifiability of the sensitivity coefficients is defined by the
span of the confidence interval; if the interval does not contain
Figure 2. Relative, steady-state sensitivity for the healthy population of in silico neuron models. Median sensitivity coefficient at steady-
state is shown for pairs of states (proteins) and parameters (rate constants). States and parameters associated with the chaperone and degradation
are not shown, as this network is not engaged when the model is behaving in a manner consistent with a healthy neuron.
doi:10.1371/journal.pcbi.1000997.g002
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small sensitivity coefficients are identifiable, most are not and the
converse is true for larger coefficients, particularly those .0.5
(Figure S5). We find that changes in synthesis rates have the
greatest positive impact on in silico homeostasis, while the
perturbations in ubiquitin-independent degradation strongly and
inversely alters the distribution of tau species. The situation for
sensitivity to phosphorylation and dephosphorylation is more
complex. Strong influences of this part of the network are found,
but they do not act in concert. For example, aberrant 3R tau has a
positive correlation with perturbations to the rate at with normal
3R tau is phosphorylated but it has an inverse relationship with the
Michaelis-Menten constant. A similar situation is seen with bound
tau states. The relationship between the microtubule interactions
and tau distribution is similarly complex.
In Figure 3, the distribution of sensitivity coefficients within the
healthy population is shown. The coefficients for each state were
consolidated and transformed by the cube root, to accommodate
the large scale and preserve the sign information of the coefficients.
For all states, .99.9% of the coefficients fall below a value of 10,
but in a few important cases high sensitivity to perturbations is
observed. These individuals are relatively more vulnerable and less
robust than the bulk of the population.
Establishing aggregation-prone neuron models
For each model of a healthy neuron, we established a
corresponding aggregation-prone model. The two models are
coupled through the microtubule binding and release parameters.
Synthesis, degradation, and phosphorylation and dephosphoryla-
tion were re-estimated because these activities are known to be
altered in neurons containing tau aggregates. In addition,
parameters associated with the chaperone and degradation
machinery were estimated.
The objective function that quantifies the behavior of an
aggregation-prone neuron is based on the data from several
experiments. Quantification of tau in adult human brains affected
by Alzheimer’s was compared to that in control and showed that
normal tau concentration was unaltered, but total tau concentra-
tion was 4–8 times normal tau; the increase is in the form of
aberrant tau [40]. The critical concentration for aggregation is
reported to be 0.2 mM [34]; necessarily, ubiquitinated tau
approaches this concentration in an aggregation-prone neuron.
The results of two silencing experiments were used to finalize the
construction of the cost function corresponding to the aggregation-
prone population [43]. In these experiments, silencing RNA was
used to reduce the levels of Hsp70 and Hsp90 in COS-1 cells over-
expressing human tau and the resulting effect on cytosolic
(unbound) and microtubule-bound tau was assessed. A 50%
reduction in Hsp70 resulted in a 5% decrease in unbound tau and
a 75% decrease in bound tau, while a 75% reduction in Hsp90
resulted in a 10% decrease in unbound tau and a 70% decrease in
bound tau [43]. The objective function was constructed as
previously, resulting in the minimization of a function that is the
sum of squared percent differences. For the ‘‘fuzzy’’ objectives, no
Figure 3. Ultrasensitivity in the populations. The cube root of the median sensitivity coefficients for each state across all parameters is shown
with coefficients exceeding a 10-fold change in a state compared to the parameter perturbation highlighted. The ultrasensitive coefficients, which are
denoted by the red and blue circled markers in the healthy and aggregation-prone populations, represent multiple individuals.
doi:10.1371/journal.pcbi.1000997.g003
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range of values.
Each result from the tuning of a neuron to healthy behavior was
used to seed an optimization run designed to generate aggrega-
tion-prone behavior. For each run, the model was initialized to the
steady-state concentrations achieved by the corresponding model
of a healthy neuron. The simulation was run until quasi-steady-
state was achieved and evaluated against the objective function to
find parameters that instantiate an aggregation-prone model
(Text S1).
In general, a single primary route to establish the aggregation-
prone behavior was not obvious. Rather, the nature of the changes
required to establish aggregation-prone neurons was multifacto-
rial, although definite trends were observed in a small subset of the
parameters (Figure 4). Confidence intervals (95%) were calculated
and show just three identifiable trends; synthesis of 4R tau is
generally increased while chaperone-independent degradation of
normal 4R tau decreased, and the relative rate at which
microtubule-bound, normal 4R tau was phosphorylated was
elevated. Relative rate is a more meaningful measure of the
change in phosphorylation and dephosphorylation processes and
thus the metric on which we focus. The consistency with which
these effects were observed suggests such behavior is likely to play
a key role in initiating the pathological changes seen in vivo. As this
result is consistent with the known increase in tau levels and
decrease in proteasomal activity, and increased kinase that occurs
in affected neurons, it provides a measure of validation for the
model and encourages efforts to test the subsequent conclusions
drawn from its behavior. In all cases, multiple perturbations in the
rates of synthesis, degradation, and phosphorylation and dephos-
phorylation were required to induce an aggregation prone state.
Sensitivity of the aggregation-prone population
The median sensitivity of the aggregation-prone population was
calculated and the 95% confidence interval of the coefficients was
used to determine their identifiability (Figures S6, S7, S8). As in
the healthy population, synthesis and degradation are important
processes with respect to tau distribution. Microtubule binding and
phosphorylation and dephosphorylation are relatively less impor-
tant in this population, although particularly for 3R tau a number
of reactions in these processes are sensitive to tau distribution.
Chaperone system reactions, on the other hand, do affect the
behavior of the aggregation-prone population. Interestingly, the
sensitivity to the aggregation reactions is only evident for
aggregates; if the toxic moiety is actually soluble, aberrant tau,
as it is increasingly thought, and not the aggregates then this has
important ramifications for the selection of drug targets as the
aggregation reactions have little effect on soluble tau.
To compare the aggregation-prone and healthy populations, the
ratios between the sensitivity coefficients in each pair of matched
individuals was calculated and the medians are shown in Figure 5.
The aggregation-prone population exceeds twice the sensitivity of
the healthy population 26% of the time and the magnitude of 46%
of the median coefficients it is 2 fold lower. Notably, in nearly 24%
of cases, the sign of the median sensitivity coefficient changes. This
sign change is a striking and important phenomenon, as it suggests
that the fundamental nature of the system’s behavior changes
during the transition from a healthy to an aggregation-prone state.
It also suggests that the effect of changing conditions in the cell,
due to drug treatment, for instance, depends on the state of the
system. For example, the sensitivity of free and bound abnormal
4R tau species to phosphorylation shows a sign change; therefore,
the efficacy of a treatment designed to influence phosphorylation
reactions may depend upon the state of the system when treatment
is initiated.
Evaluation of the distribution of the coefficients revealed subset
of individuals with very large magnitude sensitivities to changing
parameters, or ultrasensitivity (Figure 3). As with the healthy
population, .99% of individuals were more moderately impacted
by parameter perturbations, but the ultrasensitive individuals were
of a much higher magnitude in this population. Additionally, this
feature of ultrasensitivity was sharp and occurred after the
Figure 4. Parameter ratios. For parameters allowed to vary, the log2 ratios of the values in the aggregation-prone vs. the healthy population are
given. The confidence intervals, maximum, and minimum for the population are also plotted.
doi:10.1371/journal.pcbi.1000997.g004
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represent large obstacles to treatment; although sensitivity is
required of a suitable drug target, the complex nature of the
system’s behavior in combination with ultrasensitivity is a
challenging control problem and will make it difficult to re-
establish homeostasis in these individuals. Disease progression
independent of treatment is also significantly impacted by
ultrasensitivity; cognitive decline is likely to be faster due to the
fragile nature of this kind of network.
Discussion
The in silico model developed to describe tau pathophysiology
displays the very features of robustness and fragility that exist in
real biological systems and these concepts are key to our
understanding of the tauopathies. Indeed, the concept of
robustness provides a framework in which disease can be
understood as the inevitable consequence of a breakdown in the
systems that normally maintain functionality [44]. Because these
systems are complex, highly coupled, and nonlinear, their
behavior is difficult to predict and systems-level approaches are
required to understand and treat disease [45].
The population of healthy neurons is considered to be robust in
several ways. The model generates healthy behavior in a relatively
large domain of parameter space, a necessary property to maintain
a phenotype given the inherent variation and noise in all biological
systems. Likewise, the healthy population is robust and demands a
vectorial assault to become pathological, as a multitude of
perturbations to synthesis, degradation, and phosphorylation and
dephosphorylation are required to generate a corresponding
population of aggregation-prone neurons. In contrast, the
aggregation-prone population is generally more sensitive to
perturbations than the healthy population, as might be expected
for a pathological phenotype (Figure 3). Moreover, the change in
sign of a quarter of the sensitivity coefficients suggests that the
fundamental behavior of this nonlinear system changes during the
transition from healthy to aggregation-prone conditions. This
change has implications for the drug discovery process; targeting
such parts of the network is likely to be ineffective unless the timing
is carefully considered. The case study shown in Figure 6 illustrates
this point. In this individual, the binding of normally phosphor-
ylated, 3R tau to microtubules was perturbed 5-fold and the
concentration of microtubule bound, unphosphorylated 4R tau
monitored in both the healthy and aggregation-prone states; the
parameter perturbation is an in silico means of simulating drug
treatment. Not only is an inverse response observed in each
condition, but the qualitative response of the healthy neuron is in
direct opposition to that of the aggregation-prone neuron. As the
healthy and aggregation-prone neurons circumscribe the range of
behaviors expected as a tauopathy advances, it logically follows
that the sensitivity of relevant proteins to parameter perturbations
switches at some point during disease progression. Such
phenomenon may play an important role in the effectiveness of
any particular drug, whose impact may be exactly the opposite of
that intended and indeed even validated in experimental models.
Therefore the identification of potential drug targets could be
guided both by the identification of the perturbations that
contribute to generate the diseased state and by the analysis of
the parameter sensitivities in the healthy and diseased states. To
minimize undesirable system-dependent effects, we suggest to
target parameters for which the sign of the sensitivity coefficients
does not change between the healthy and aggregation-prone
states. Having identified synthesis, degradation, phosphorylation/
dephosphorylation as keys to disease progression, the sensitivity
coefficient associated synthesis and degradation reactions ap-
peared to have a minimal number of changes of sign compared to
Figure 5. Sensitivity ratios. The ratio of the relative, median sensitivity coefficient for the aggregation prone population to the healthy population
is shown for each state (protein concentration) and parameter (rate constant) pair.
doi:10.1371/journal.pcbi.1000997.g005
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(Figure 5). From that point of view, synthesis and degradation
appear to be preferential drug targets within the tau network.
A subset of the aggregation-prone population displays extreme
fragility (Figure 3). This ultrasensitivity arises in the models of
aggregation-prone neurons, and thus has implications for disease
progression; the typical delay in diagnosing neurodegenerative
diseases makes this phenomena potentially important with respect
to treatment. While it is important to develop drugs that target
sensitive points in biological networks, the widespread ultrasensi-
tivity and nonlinearity observed in a subset of the population are
likely to make the response of these systems difficult to predict or
control, and they are likely to be highly resistant to rescue.
The robustness of the tau network and the multifactorial nature
of its vulnerability to pathological change presents a challenge to
the selection of drug targets, and for a subset of patients the disease
is likely to be nearly impossible to reverse after the network
becomes ultrasensitive. The model analysis also suggests that
stalling or reversing tau pathophysiology will be further compli-
cated by the timing at which the intervention is begun; a treatment
may have an opposite effect on the system than is expected due to
the sign inversion observed for some sensitivity coefficients.
The systems biology approach we have taken here has
highlighted the complex, nonlinear behavior that cellular networks
can display and suggests the difficulties the pharmaceutical and
biotechnology industries will face in attempting to treat diseases
associated with their aberrant functioning. By modeling both the
physiological and the pathological functioning of the network
governing tau function, we have shown that the biological
response to a perturbation is dependent on the condition of the
network and that, therefore, the time at which a compensatory
perturbation is made is potentially significant. This implication is
particularly relevant in therapeutic treatment timing and ap-
proach. The population-based analyses we have completed also
highlights the importance of variability in the study and treatment
of disease and the need to characterize the variability of the
network components, such as reaction rates, to more fully
elucidate its nature. Such variations are distinct from stochastic
variation and the extent of the variability is likely dependent on the
biological network and the particular network component. From a
modeling perspective, in silico populations can be created for any
model in a straightforward manner, by retaining not just a single
optimization result but a number of results that fit the data almost
equally well. As new experimental data is generated, the variation
within the in silico populations will become more constrained and
approach that seen in vivo. With respect to the optimization results,
they suggest an approach that considers fitting matched measure-
ments from the same individuals, for example if data was collected
from individual animals over time, rather than taking a
conglomerated value over measurements from multiple individu-
als. The computational, model-based approach to exploring
cellular networks demonstrates a new paradigm for understanding
disease that is likely to become increasingly effective as high-
throughput and sequencing technologies quickly generate large
databases of experimental data from which progressively more
detailed, accurate models can be built.
Methods
Current knowledge about the molecular biology of tau protein
was integrated into a deterministic, kinetic model that was realized
as a set of 45 ordinary differential equations (ODE’s) (Tables S1
and S2) and implemented in MATLAB (Mathworks, Cambridge,
UK). For each species, a differential equation was constructed
from the rate equations for all reactions in which the species is
involved; the reactions were modeled with mass action and
Michaelis-Menten type kinetics. For example, a representative
equation for the time-evolution of unphosphorylated tau is given
Figure 6. Time-dependent response to perturbations. A 5-fold increase in the parameter associated with the binding of normally
phosphorylated, 3R tau to microtubules was applied and the response of unphosphorylated, microtubule bound 4R tau was monitored with respect
to the basal concentration of this species. The perturbation results in a decrease in concentration with respect to basal in the healthy neuron, while in
the aggregation-prone neuron, an increase in protein concentration is observed.
doi:10.1371/journal.pcbi.1000997.g006
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of unphosphorylated tau due to its synthesis, degradation, a
conformational change that precedes microtubule binding, the
restoration of the original protein conformation, phosphorylation,
and dephosphorylation.
To validate the model construction effort, we used the method of
Jacquez and Greif [46] to evaluate the a priori identifiability of the
model and extended it to develop a suitable substitute for structural
identifiability, as direct methods for evaluating structural identifia-
bility are not feasible for large, nonlinear models such as this. In the
traditional approach to a priori identifiability analyses, an iterative
process of estimation and identifiability analysis is employed,
reducing the number of parameters in the model after each
iteration until the model is entirely identifiable [47]. We used a
pseudo-global extension of this approach to diminish the parameter
dependence of the results. First, Sobol’ Low Discrepancy Sequences
were used to generate 1024 points in parameter space. For each
point, an in silico experiment in which tau was allowed to equilibrate
for 2 hours after being induced in a tau-free system was simulated.
We assumed all states were measurable and measured at 30-minute
intervals during the 2 hour experiment. In addition, the local
parametric sensitivity of the system was evaluated. From these
simulated data, the correlation matrix Mc that establishes a priori
identifiability was calculated according to Eq. S3 (Text S1).
Identifiable systems have correlations strictly , |1|. Here, the
average correlation matrix is used to ascertain the identifiability
of the system. Because the parameter sets were randomly
generated, the resulting systems do not necessarily display
biologically relevant behavior; therefore, the optimization objec-
tive function was calculated at each point in parameter space and
used as weighting factors in calculating the average correlation.
Given the model structure we established and the bounds on the
parameter ranges, we can conclude that the model is a priori
identifiable, but the high correlations between some parameters
suggest that they might be difficult to estimate and therefore one
parameter in each pair with a correlation .|0.95| was removed
from the optimization and fixed to its nominal value.
Using this framework, that reduces parametric dependence and
assumes all states are experimentally measurable, a priori
identifiability is an acceptable proxy for structural identifiability.
However the converse is not true and no conclusions can be drawn
from a non-a priori identifiable system, as different experiments
could reveal that the system is indeed structurally identifiable.
The model parameters were numerically fit using a hybrid
stochastic-deterministic global optimization method [48,49] that is
based on well-established scatter search methods and implemented
as a set of MATLAB functions, which are freely available on the
authors’ website and require only a single function call in MATLAB
to implement. In brief, the method iterates between a global scatter
search and local refinement of the solution using traditional
methods; in this case we used MATLAB’s fmincon, which is
gradient-based technique, to perform this refinement. Although
someexperimentallyderived kineticdatawas available, itoriginated
from heterogeneous sources including in vitro and in vivo platforms
and under different experimental conditions. Therefore, generous
bounds were used to define and explore parameter space.
To assess the effect of parameter perturbations on the steady-
state concentrations of protein in the healthy population and
quasi-steady-state (due to the polymerization reaction) concentra-
tion in the aggregation-prone population, the local, relative
sensitivity of this system, given by Eq. S4 (Text S1), was evaluated.
The relative sensitivity coefficient gives the dependence of the
protein concentration, ‘‘xi’’, on a parameter, ‘‘pj’’ and is
normalized with respect to the parameter and state values to
facilitate. The non-normalized coefficients are calculated by
applying the chain rule to Eq. S4 (Text S1), which results in a
set of ordinary differential equations that give all the sensitivity
coefficients associated with this system (Eq. S5, Text S1) by
simultaneous integration of these sensitivity ODE’s and the model
ODE’s in MATLAB. The sensitivity coefficients at steady-state
were collected into a matrix, Sx, of size Nx (number of states) by Np
(number of parameters).
Supporting Information
Table S1 List of states, differential equations governing the time
evolution of the states, and initial conditions for each state.
Found at: doi:10.1371/journal.pcbi.1000997.s001 (0.11 MB PDF)
Table S2 List of reactions and the rate equations for the model
of tau pathophysiology.
Found at: doi:10.1371/journal.pcbi.1000997.s002 (0.18 MB PDF)
Text S1 Supporting equations for the construction of the ODE’s
and objective function and for the calculation of the correlation
matrices and sensitivity coefficients.
Found at: doi:10.1371/journal.pcbi.1000997.s003 (0.03 MB PDF)
Figure S1 Major events in the tau processing network.
Phosphorylated (P) tau reversibly binds microtubules. In degen-
erating neurons, tau becomes abnormally and hyper-phosphory-
lated, misfolds, and is taken up by the chaperone system. Hsc70
mediates a decision between rescue and degradation.
Found at: doi:10.1371/journal.pcbi.1000997.s004 (0.10 MB TIF)
Figure S2 Pseudo-global identifiability for the first stage of
optimization to generate a population of healthy neuron models.
The matrix shows the correlation between all pairs of parameters
estimated during the optimization. A correlation of 1 or -1
indicates a non-identifiable parameter. No parameters were non-
identifiable, but parameters that were highly correlated, i.e. .0.95
(circled), were nonetheless removed to improve the efficiency of
the optimization.
Found at: doi:10.1371/journal.pcbi.1000997.s005 (1.20 MB TIF)
Figure S3 Pseudo-global identifiability for the second stage of
optimization to generate a population of aggregation-prone
neuron models. The matrix shows the correlation between all
pairs of parameters estimated during the optimization. A
correlation of 1 or -1 indicates a non-identifiable parameter. No
parameters were non-identifiable, nor did any parameter pairs
have correlations greater than 0.95.
Found at: doi:10.1371/journal.pcbi.1000997.s006 (1.60 MB TIF)
Figure S4 Identifiability of the median sensitivity coefficients for
the healthy population, as computed from the 95% confidence
intervals.
Found at: doi:10.1371/journal.pcbi.1000997.s007 (0.32 MB TIF)
Figure S5 Distribution of the median sensitivity coefficients,
categorized by their identifiability.
Found at: doi:10.1371/journal.pcbi.1000997.s008 (0.07 MB TIF)
Figure S6 Relative, steady-state sensitivity for the aggregation-
prone population of in silico neuron models. Median sensitivity
coefficient at steady-state is shown for pairs of states (proteins) and
parameters (rate constants). The parameters are grouped accord-
ing to type.
Found at: doi:10.1371/journal.pcbi.1000997.s009 (0.80 MB TIF)
Figure S7 Identifiability of the sensitivity coefficients, as
computed from the 95% confidence intervals. If the confidence
interval spanned 0, the coefficient was labeled unidentifiable.
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Figure S8 Distribution of the median sensitivity coefficients of
the aggregation-prone population according to their identifiability
and magnitude.
Found at: doi:10.1371/journal.pcbi.1000997.s011 (0.08 MB TIF)
Dataset S1 Optimization results.
Found at: doi:10.1371/journal.pcbi.1000997.s012 (8.36 MB
XLSX)
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